Femara — Competitive Intelligence Brief

Femara (letrozole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase Inhibitor [EPC]. Area: Oncology.

marketed Aromatase Inhibitor [EPC] Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial Oncology Small molecule

Target snapshot

Femara (letrozole) — Novartis AG. Third-generation aromatase inhibitor that blocks estrogen biosynthesis by inhibiting the aromatase enzyme (CYP19A1).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Femara TARGET	letrozole	Novartis AG	marketed	Aromatase Inhibitor [EPC]	Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial	1997-07-25
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Aromasin	exemestane	Pfizer	marketed	Aromatase Inhibitor [EPC]	Aromatase	1999-01-01
LETROZOLE	LETROZOLE		marketed	Aromatase Inhibitor [EPC]		1997-01-01
Arimidex	anastrozole	AstraZeneca	marketed	Aromatase inhibitor	Aromatase enzyme	1995-12-27
ANASTROZOLE	ANASTROZOLE		marketed	Aromatase Inhibitor [EPC]	aromatase	1995-01-01
Teolit	TESTOLACTONE		marketed	Aromatase Inhibitor	Aromatase	1969-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase Inhibitor [EPC] class)

1. · 2 drugs in this class
2. Al-Azhar University · 1 drug in this class
3. Novartis AG · 1 drug in this class
4. Pfizer · 1 drug in this class